Success Stories: Thanks to Our Experts, an Associate Professor from Taiwan Working in Pathology with Over 2,900 Citations for his Publications Obtains NIW Confirmation without RFE

Client’s Testimonial:

“Thank you very much, and it was my pleasure to work with such a great team.”

On April 4^th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for an Associate Professor in the Field of Pathology (Approval Notice).

General Field: Pathology

Position at the Time of Case Filing: Associate Professor

Country of Origin: Taiwan

Country of Residence at the Time of Filing: Taiwan

Approval Notice Date: April 4^th, 2022

Processing Time: 3 months, 13 days

Case Summary:

As an expert in the field of pathology, our NIW (National Interest Waiver) client from Taiwan’s proposed endeavor was to continue to develop comprehensive molecular profiling approaches to discovering diagnostic biomarkers and therapeutic targets for precision in the treatment of cancer. So, it was apparent that his proposed endeavor is of great importance because it contributes to the effective treatment of gynecological cancers such as ovarian cancer. Gynecological cancers account for nearly one-fifth of all new cancer cases worldwide and cause just under 3 million deaths annually.

Our team had the task to ensure the success of his case and we did so by making a list of his achievements. This list contained the following data which helped in the quick adjudication of his case:

His proposed research of developing comprehensive molecular profiling approaches to discovering diagnostic biomarkers and therapeutic targets for the precision treatment of cancer, therefore, has substantial merit.
His proposed endeavor also has broad implications for the United States. His research on cancer treatments, generally, disproportionately benefits the United States, which has a high age-adjusted cancer rate compared to most other countries.
Due to its clear national importance, his research has in fact been supported with funding from the United States Department of Defense, the National Institutes of Health, the American Cancer Society, the Honorable Tina Brozman Foundation, the Ovarian Cancer Research Alliance, the Gray Foundation, and the John Templeton Foundation.
He has completed at least 13 reviews to date for well-known journals in his area of study.
His research has resulted in 116 peer-reviewed journal articles (14 of them first-authored and 3 corresponding-authored).
His publications have been cited a massive total of 2,919 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of pathology.
He has pursued research directly related to his proposed endeavor of developing comprehensive molecular profiling approaches to discovering diagnostic biomarkers and therapeutic targets for the precision treatment of cancer for 11 years.

While these specific research contributions represent only a subset of his most successful endeavors, these projects are indicative of the overall quality of his research and illustrate his particular expertise and ability to continue contributing significantly to his field and to advancing the proposed endeavor. The evidence thus shows that his research holds significant value for the treatment of cancers and for the U.S. pharmaceutical industry. This argument helped our case and won him the NIW approval only 3 months and 13 days later.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.